Discovery of tertiary aminoacids as dual PPARα/γ agonists-I

被引：12

作者：

Devasthale, Pratik V. ^{[1
]}

Chen, Sean ^{[1
]}

Jeon, Yoon ^{[1
]}

Qu, Fucheng ^{[1
]}

Ryono, Denis E. ^{[1
]}

Wang, Wei ^{[1
]}

Zhang, Hao ^{[1
]}

Cheng, Lin ^{[1
]}

Farrelly, Dennis ^{[1
]}

Golla, Rajasree ^{[1
]}

Grover, Gary ^{[1
]}

Ma, Zhengping ^{[1
]}

Moore, Lisa ^{[1
]}

Seethala, Ramakrishna ^{[1
]}

Sun, Wei ^{[1
]}

Doweyko, Arthur M. ^{[1
]}

Chandrasena, Gamini ^{[1
]}

Sleph, Paul ^{[1
]}

Hariharan, Narayanan ^{[1
]}

Cheng, Peter T. W. ^{[1
]}

机构：

[1] Bristol Myers Squibbs Pharmaceut Res Inst, Princeton, NJ 08543 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2007年 / 17卷 / 08期

关键词：

PPAR; PPAR alpha/gamma dual agonists; antidiabetic; oxybenzylglycines;

D O I：

10.1016/j.bmcl.2007.01.060

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A novel series of potent dual agonists of PPAR alpha and PPAR gamma, the alkoxybenzylglycines, was identified and explored using a solution-phase library approach. The synthesis and structure-activity relationships of this series of dual PPAR alpha/gamma agonists are described. (c) 2007 Elsevier Ltd. All rights reserved.

引用

页码：2312 / 2316

页数：5

共 21 条

[1] Reductive amination of aldehydes and ketones with sodium triacetoxyborohydride. Studies on direct and indirect reductive amination procedures [J].

AbdelMagid, AF ;

Carson, KG ;

Harris, BD ;

Maryanoff, CA ;

Shah, RD .

JOURNAL OF ORGANIC CHEMISTRY, 1996, 61 (11) :3849-3862

[2] FENOFIBRATE - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES AND THERAPEUTIC USE IN DYSLIPIDEMIA [J].

BALFOUR, JA ;

MCTAVISH, D ;

HEEL, RC .

DRUGS, 1990, 40 (02) :260-290

[3]

Balfour JAB, 1999, DRUGS, V57, P921

[4] Identification of peroxisome proliferator-activated receptor ligands from a biased chemical library [J].

Brown, PJ ;

Smith-Oliver, TA ;

Charifson, PS ;

Tomkinson, NCO ;

Fivush, AM ;

Sternbach, DD ;

Wade, LE ;

Orband-Miller, L ;

Parks, DJ ;

Blanchard, SG ;

Kliewer, SA ;

Lehmann, JM ;

Willson, TM .

CHEMISTRY & BIOLOGY, 1997, 4 (12) :909-918

[5] Muraglitazar, a dual (α/γ) PPAR activator:: A randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes [J].

Buse, JB ;

Rubin, CJ ;

Frederich, R ;

Viraswami-Appanna, K ;

Lin, KC ;

Montoro, R ;

Shockey, G ;

Davidson, JA .

CLINICAL THERAPEUTICS, 2005, 27 (08) :1181-1195

[6] PPARs as targets for metabolic and cardiovascular diseases [J].

Cheng, PTW ;

Mukherjee, R .

MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2005, 5 (08) :741-753

[7]

CHENGLAI A, 2000, HEART DIS, V2, P3

[8]

Després JP, 2001, AM J CARDIOL, V88, p30N

[9] Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [muraglitazar BMS-298585], a novel peroxisome proliferator-activated receptor α/γ dual agonist with efficacious glucose and lipid-lowering activities [J].

Devasthale, PV ;

Chen, S ;

Jeon, Y ;

Qu, FC ;

Shao, CN ;

Wang, W ;

Zhang, H ;

Cap, M ;

Farrelly, D ;

Golla, R ;

Grover, G ;

Harrity, T ;

Ma, ZP ;

Moore, L ;

Ren, J ;

Seethala, R ;

Cheng, L ;

Sleph, P ;

Sun, W ;

Tieman, A ;

Wetterau, JR ;

Doweyko, A ;

Chandrasena, G ;

Chang, SY ;

Humphreys, WG ;

Sasseville, VG ;

Biller, SA ;

Ryono, DE ;

Selan, F ;

Hariharan, N ;

Cheng, PTW .

JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (06) :2248-2250

[10] Recent developments and emerging therapies for type 2 diabetes mellitus. [J].

Evans A.J. ;

Krentz A.J. .

Drugs in R & D, 1999, 2 (2) :75-94

← 1 2 3 →